China approves 2nd COVID-19 vaccine for general public use

SinoVac's CoronaVac vaccine.
(Image credit: CARL DE SOUZA/AFP via Getty Images)

The Chinese government has authorized the COVID-19 vaccine developed by Sinovac Biotech for general public use, the company said Saturday. Sinovac's jab, which requires a two-dose regimen, will be the second coronavirus vaccine approved in China, though it appears the findings merit some skepticism.

The green light is based on results from two months' worth of late-stage trials in Brazil, Turkey, Indonesia, and Chile, and Sinovac said final analysis data is not yet available and more confirmation on safety results is needed. The trial results, which were light on details, varied fairly significant depending on the country — the vaccine was found to be just over 50 percent effective in Brazil, 91 percent in Turkey (that figure is based on a preliminary analysis of just 29 cases), and 65 percent in Indonesia.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.